Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 457 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: venetoclax Clear all
Recruiting Phase 3 Interventional

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Interventions
Nemtabrutinib, Venetoclax, Rituximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
6
States / cities
Springdale, Arkansas • Long Beach, California • Pembroke Pines, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

NCT04285567
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Obinutuzumab, Venetoclax, Fludarabine, Cyclophosphamide, Rituximab, Bendamustine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

NCT05909553
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jul 24, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, Acalabrutinib, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

NCT03926624
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Recruiting No phase listed Observational

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

NCT06279572
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Recruiting No phase listed Observational

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Biospecimen samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax Plus Inotuzumab for B-ALL

NCT05016947
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
Interventions
Venetoclax, Dexamethasone, Inotuzumab Ozogamicin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

NCT04493099
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Alvocidib Hydrochloride, Decitabine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
18
States / cities
Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05211570
View directory record Official record
Conditions
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions
AB8939, Venetoclax
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

NCT02717624
View directory record Official record
Conditions
Mantle Cell Lymphoma (MCL)
Interventions
Acalabrutinib in combination with BR, Acalabrutinib in combination with VR
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Louisville, Kentucky • Ann Arbor, Michigan • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

NCT04188405
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Decitabine, Ponatinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 1 Interventional

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

NCT05053659
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Loncastuximab tesirine, Venetoclax
Drug
Lead sponsor
Paolo Caimi, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

NCT04336982
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
CC-90009, Venetoclax, Azacitidine, Gilteritinib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

NCT05391750
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Tocilizumab, Venetoclax
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ibrutinib + Venetoclax in Untreated WM

NCT04273139
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation
Interventions
IBRUTINIB, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

NCT03181126
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma
Interventions
Navitoclax, Chemotherapy, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
4 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 24, 2026, 4:13 AM EDT
Not yet recruiting Phase 2 Interventional

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

NCT07605949
View directory record Official record
Conditions
Leukemia Acute Myeloid
Interventions
Azacitidine, Venetoclax, Revumenib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
635
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 434 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821
View directory record Official record
Conditions
CLL
Interventions
Sonrotoclax, Zanubrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
40
States / cities
Anchorage, Alaska • Duarte, California • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Recruiting Phase 1 Interventional

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

NCT05342584
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Venetoclax Oral Tablet, Daunorubicin, Cytarabine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 24, 2026, 4:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

NCT02427451
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Interventions
Bcl-2 Inhibitor GDC-0199, Obinutuzumab, Ibrutinib, Pharmacological Study, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Kerry Rogers
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 24, 2026, 4:13 AM EDT